177Lu-PSMA Therapy for Metastatic Testicular Mixed Germ Cell Tumor.
Dipeptides
/ therapeutic use
Heterocyclic Compounds, 1-Ring
/ therapeutic use
Humans
Lutetium
Male
Middle Aged
Neoplasm Metastasis
Neoplasms, Germ Cell and Embryonal
/ diagnostic imaging
Positron Emission Tomography Computed Tomography
Prostate-Specific Antigen
Prostatic Neoplasms
/ pathology
Testicular Neoplasms
/ diagnostic imaging
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 May 2021
01 May 2021
Historique:
pubmed:
26
2
2021
medline:
29
4
2021
entrez:
25
2
2021
Statut:
ppublish
Résumé
Prostate-specific membrane antigen (PSMA) overexpression in various tumors are demonstrated in both in vitro and in vivo studies. Prostate-specific membrane antigen-directed radionuclide therapies are generally used in prostate cancer and could be also useful in PSMA-avid other malignancies. Herein, we present a case of a 46-year-old male patient who had progressive metastatic testicular mixed germ cell tumor, despite repeated operations and treatments. 68Ga-PSMA PET/CT was performed to assess eligibility for 177Lu-PSMA therapy. Patient had intense PSMA uptake in metastatic lesions, and 177Lu-PSMA has been given to control of disease. However, α-fetoprotein level progressed, and mixed therapy response was detected in 68Ga-PSMA PET/CT.
Identifiants
pubmed: 33630811
doi: 10.1097/RLU.0000000000003563
pii: 00003072-202105000-00012
doi:
Substances chimiques
177Lu-PSMA-617
0
Dipeptides
0
Heterocyclic Compounds, 1-Ring
0
Lutetium
5H0DOZ21UJ
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
415-418Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Friedlander TW, Small E. Testicular cancer. In: Abeloff’s Clinical Oncology . Philadelphia, PA: Elsevier; 2020:1442–1467.e1445.
Chieffi P, De Martino M, Esposito F. New anti-cancer strategies in testicular germ cell tumors. Recent Pat Anticancer Drug Discov . 2019;14:53–59.
Kuyumcu S, Has-Simsek D, Iliaz R, et al. Evidence of prostate-specific membrane antigen expression in hepatocellular carcinoma using 68 Ga-PSMA PET/CT. Clin Nucl Med . 2019;44:702–706.
Shetty D, Loh H, Bui C, et al. Elevated 68 Ga prostate-specific membrane antigen activity in metastatic non–small cell lung cancer. Clin Nucl Med . 2016;41:414–416.
Kabasakal EDL, Kanmaz MHB. 68 Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging . 2014;41:1461–1462.
Chang SS, Reuter VE, Heston W, et al. Five different anti–prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res . 1999;59:3192–3198.
Kinoshita Y, Kuratsukuri K, Landas S, et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg . 2006;30:628–636.
de Vries LH, Lodewijk L, Braat AJAT, et al. 68 Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177 Lu-PSMA-617. EJNMMI Res . 2020;10:1–8.
Has Simsek D, Kuyumcu S, Agaoglu FY, et al. Radionuclide therapy with 177 Lu-PSMA in a case of metastatic adenoid cystic carcinoma of the parotid. Clin Nucl Med . 2019;44:764–766.
Kumar A, Ballal S, Yadav MP, et al. 177 Lu-/ 68 Ga-PSMA theranostics in recurrent glioblastoma multiforme: proof of concept. Clin Nucl Med . 2020;45:e512–e513.